Disruptive Technology Channel Gilded Age of Genomics Just Getting Started By Tom LydonSeptember 27, 2021
Disruptive Technology Channel Google Getting Into Genomics? It Already Is By Tom LydonSeptember 8, 2021
Disruptive Technology Channel Early Cancer Detection: Major Opportunity for Genomics Investors By Tom LydonSeptember 3, 2021
Disruptive Technology Channel Genomics Advancements Could Aid Breast Cancer Prevention By Tom LydonAugust 4, 2021
Disruptive Technology Channel Unpacking the Potential of the Synthetic Biology Space By Tom LydonJuly 21, 2021
Disruptive Technology Channel How Healthcare ETFs Can Get Their Swagger Back By Tom LydonJuly 14, 2021
Disruptive Technology Channel The ARKG ETF and the Intersection of All Things Tech By Tom LydonJuly 13, 2021
Disruptive Technology Channel Play the New Era of Gene Editing with the ARKG ETF By Tom LydonJuly 2, 2021
Disruptive Technology Channel New Gene Editing Trial Results Bump the ARKG ETF By Tom LydonJune 29, 2021
Disruptive Technology Channel Biogen Alzheimer’s Approval Could Signal FDA’s Flexibility By Tom LydonJune 15, 2021
Disruptive Technology Channel Pandemic Opening the Door for Widespread Genetic Testing By Tom LydonJune 2, 2021
Disruptive Technology Channel A Base Hit: How Base Editing Is Changing Genomics By Tom LydonMay 26, 2021
Disruptive Technology Channel How Genomics Is Improving Cancer Screening, Investing By Tom LydonMay 18, 2021
Disruptive Technology Channel Is This Ark Invest ETF a Sustainable Investing Play? By Tom LydonMay 13, 2021
Disruptive Technology Channel Accelerating Gene Therapies? There’s an ETF for That By Tom LydonMay 5, 2021
Disruptive Technology Channel Long Read Sequencing Is Securing a Long Runway for ‘ARKG’ By Tom LydonApril 27, 2021
Disruptive Technology Channel A Dynamic Duo that Could Power ‘ARKG’ Higher By Tom LydonApril 15, 2021